Your session is about to expire
← Back to Search
Brachytherapy
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC) (TheraSphere Trial)
N/A
Waitlist Available
Led By Robert C. Martin, MD
Research Sponsored by University of Louisville
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up review all standard of care ct scans to evaluate tumor response after treatment
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
Eligible Conditions
- Liver Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ monitor for toxicities to therasphere
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~monitor for toxicities to therasphere
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Tumor Response after treatment
Secondary study objectives
Determine proportion of patients with HCC that can be treated with Therasphere
Evaluate survival time
Incidence of toxicities / Adverse Events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TheraSphereExperimental Treatment1 Intervention
TheraSphere
Find a Location
Who is running the clinical trial?
University of LouisvilleLead Sponsor
348 Previous Clinical Trials
77,195 Total Patients Enrolled
1 Trials studying Liver Cancer
MDS Pharma ServicesIndustry Sponsor
12 Previous Clinical Trials
1,860 Total Patients Enrolled
Robert C. Martin, MDPrincipal InvestigatorUniversity of Louisville